Novartis Hopes Eye Drug Beovu Bounces Back After New Approval
Gets EU Okay For Diabetic Macular Edema
Executive Summary
Having struggled to allay safety concerns for its use in wet age-related macular degeneration, the Swiss major has faith Beovu's efficacy and less frequent dosing will prove more than a match for established DME rival Eylea and newcomer Vabysmo.
You may also be interested in...
Shilpa Medicare’s Plan For Eylea Biosimilar Spells Ambition, But Path Not Easy
Shilpa Medicare’s plan for trials of an Eylea biosimilar shows the company’s ambition to leapfrog to a biosimilars-led growth strategy, one that Indian majors like Cipla and Lupin pivoted to post a successful generics program. However, the path isn’t going to be easy and Biocon/Viatris, Samsung Biologics are ahead
Carogra, Xenpozyme Among Japan World-First Approvals
The latest batch of new drug approvals in Japan includes several products receiving their first marketing clearances globally, notably a new oral competitor to a blockbuster ulcerative colitis drug and a high-need therapy for the rare disease ASMD.
Novartis Restructure Sees Drug Development And Oncology Chiefs Exit
Tsai and Schaffert out as the Swiss giant looks to maximize returns from its US business, and find more transformational drugs with the help of a new ‘strategy and growth officer’.